<DOC>
	<DOC>NCT01925755</DOC>
	<brief_summary>This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous System) systemic embolism prevention in patients with AF (Atrial fibrillation) and prior stroke or TIA (Transient Ischemic attack) who treat with rivaroxaban at an initial visit and three follow-up visits.</brief_summary>
	<brief_title>Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male and female patients ≥ 18 years old who start treatment with rivaroxaban Nonvalvular Atrial Fibrillation is documented in patients' file Prior TIA/Stroke history TIA more than 72 hours after documented TIA more than 2 weeks after nonhemorrhagic stroke Written informed consent Contraindications for use of Xarelto® in accordance with approved product label Previous thromboprophylaxis treatment with anticoagulants prior toby reason of stroke / TIA prevention Any reasons of medical and nonmedical character, which in the opinion of the physician can hamper patient participation in NIS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-interventional</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Prevention in prior stroke or TIA</keyword>
	<keyword>Russian Federation</keyword>
</DOC>